The incidence of allergies is increasing, particularly in industrialized areas. Allergic inflammation can differ substantially in intensity. Traditional drug therapy such as antihistamines, corticosteroids, anticholinergic agents and leukotriene inhibitors is important in reducing and preventing symptoms and is essential in acute use. More recent therapies including anti-immunoglobin E (IgE) therapy, anti-interleukin (IL) monoclonal antibodies, and phosphodiesterase 4/phospholipaseA2 inhibitors, have improved outcomes. However, in order to develop more effective therapies, further research is needed into the molecular mechanisms underlying allergy onset, particularly in terms of intracellular reactions and the cytosolic Ca2+ balance.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
The role of eosinophils in physiology and disease: Is complete depletion of eosinophils the goal?
Watch Dr Enrico Heffler describe how eosinophilic inflammation can be targeted for the treatment of inflammatory respiratory diseases.
- Understand the dynamics of eosinophils across the human body in wellness and disease
- Discuss clinical scenarios in which eosinophilic therapy may be beneficial
- Recognize how new eosinophilic therapies offer promise for the future treatment of eosinophil-mediated diseases
Drew Bird, AAAAI 2021: Hot Topics in Pediatric Food Allergy
We were delighted to meet with Drew Bird (Associate Professor of Pediatrics, Division of Allergy & Immunology, UT Southwestern Medical Center, Dallas, TX, USA) to discuss the current hot topics in pediatric food allergy. The workshop entitled ‘Hot Topics in Pediatric Food Allergy‘ was presented at the American Academy of Allergy, Asthma & Immunology Virtual […]
Philippe Bégin, AAAAI 2021: Epicutaneous Immunotherapy for Peanut Allergy
We were delighted to catch up with Philippe Bégin (CHU Sainte-Justine, Montréal, Canada) to discuss the use of epicutaneous immunotherapy for peanut allergy. The abstract entitled ‘Reduction in Severity Following 12 Months of Epicutaneous Immunotherapy for Peanut Allergy‘ (ABSTRACT NUMBER: 342) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, […]
Philippe Bégin, AAAAI 2021: PEPITES Trial Results
TouchIMMUNOLOGY caught up with Philippe Bégin (CHU Sainte-Justine, Montréal, Canada) to discuss the PEPITES trial results, investigating epicutaneous immunotherapy for peanut allergy in children. The abstract entitled ‘Reduction in Severity Following 12 Months of Epicutaneous Immunotherapy for Peanut Allergy‘ (ABSTRACT NUMBER: 342) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!